--- url: 'https://qubit.capital/blog/us-series-b-plus-weekly-funding-roundup-week-4-april-2026-2' title: 'US Series B+ Weekly Funding Roundup (Apr 21-28, 2026): $475.0M Raised Across 6 Deals' author: name: Sagar Agrawal url: 'https://qubit.capital/blog/author/sagar' date: '2026-04-28T03:17:57+05:30' modified: '2026-04-28T11:20:33+05:30' type: post summary: 'Six US late-stage deals raised $475M this week, led by Omni''s $120M Series C and Tortugas Neuroscience''s $100M biotech launch.' categories: - Weekly Funding Roundup image: 'https://qubit.capital/wp-content/uploads/2026/04/featured-us-series-bplus-66354.webp' published: true --- # US Series B+ Weekly Funding Roundup (Apr 21-28, 2026): $475.0M Raised Across 6 Deals Six US late-stage rounds closed between April 21 and April 28, 2026, pulling in a combined $475 million. Healthtech took four of the six slots, with biotech, medtech commercial software, gene therapy and biopharma CRM all drawing nine-figure conviction. The other two deals went to a modern BI platform and a facial-authentication hardware vendor, a reminder that infrastructure software and physical-security AI are still raising real money even as the consumer-AI cycle absorbs most of the headlines. The week’s late-stage activity sat alongside lighter early-stage flow in the same geography. US seed rounds totaled $144.5M across six companies and US Series A activity added $109.0M across four deals, so growth-stage capital outweighed early-stage by more than two-to-one. That mix tracks what we’ve seen all of April: founders with clinical data, paying customers, or repeat-founder credibility are clearing rounds, while pre-revenue stories are taking longer. Weekly Funding Roundup APR 21-28, 2026 $475M TOTAL RAISED 6DEALS CLOSED MixedSTAGE $79.2MAVG DEAL SIZE USTOP REGION BY STAGE Series C$200M42% Series B+$125M26% Series B+ (launch financing)$100M21% Series B$50M11% BY SECTOR OmniSaaS / business intelligence$120M UnknownHealthtech / biotech$100M AcuityMDHealthtech / medtech commercial software$80M Ray TherapeuticsHealthtech / gene therapy$75M Courier HealthHealthtech / biopharma SaaS$50M Alcatraz AICybersecurity / physical access control$50M Table of Contents - [1. Omni Raises $120M For AI-Native BI](#1-omni-raises-$120m-for-ai-native-bi) [Deal Overview](#deal-overview) - [Investor Profile](#investor-profile) - [Company and Leadership](#company-and-leadership) - [Problem and Opportunity](#problem-and-opportunity) - [Product and Technology](#product-and-technology) - [Use of Proceeds and Vision](#use-of-proceeds-and-vision) - [Market Context](#market-context) - [2. Tortugas Neuroscience Launches With $100M For CNS Pipeline](#2-tortugas-neuroscience-launches-with-$100m-for-cns-pipeline) [Deal Overview](#deal-overview-1) - [Investor Profile](#investor-profile-1) - [Company and Leadership](#company-and-leadership-1) - [Problem and Opportunity](#problem-and-opportunity-1) - [Product and Technology](#product-and-technology-1) - [Use of Proceeds and Vision](#use-of-proceeds-and-vision-1) - [Market Context](#market-context-1) - [3. AcuityMD Raises $80M Series C At $955M Valuation](#3-acuitymd-raises-$80m-series-c-at-$955m-valuation) [Deal Overview](#deal-overview-2) - [Investor Profile](#investor-profile-2) - [Company and Leadership](#company-and-leadership-2) - [Problem and Opportunity](#problem-and-opportunity-2) - [Product and Technology](#product-and-technology-2) - [Use of Proceeds and VisionThe plan is to extend AI-agent capabilities, grow the field-sales and customer-success teams, expand internationally and move into adjacent products like marketing and market access. The pitch to investors is that AcuityMD becomes the Veeva of medical devices.Market ContextThe global medical-device market clears $600B+ annually and employs thousands of commercial reps. Veeva has limited medtech presence; the rest of the field is Definitive Healthcare, IQVIA, H1 and a long tail of in-house BI builds.4. Ray Therapeutics Adds $75M For Optogenetic Vision RestorationDeal OverviewStage: Series B+Sector: Healthtech / gene therapyGeography: South San Francisco, USRound size: $75MInvestors: Deerfield Management, Norwest Venture Partners, Casdin CapitalInvestor ProfileDeerfield, Norwest and Casdin all extended from prior rounds. The syndicate is unusually concentrated for a clinical-stage biotech, which suggests strong conviction from existing backers rather than a competitive new-money round.Company and LeadershipRay Therapeutics was founded in 2021 by CEO Paul Bresge with scientific co-founders from UC Berkeley who pioneered optogenetics. The company has been operating in South San Francisco since launch.Problem and OpportunityRetinitis pigmentosa affects roughly 1 in 4,000 people globally and has no broadly approved treatment. Luxturna works only for patients with a specific RPE65 mutation. Most RP patients have nothing.Product and TechnologyRay's approach is mutation-agnostic. AAV vectors deliver light-sensitive opsins to retinal cells, restoring some level of vision regardless of which gene is broken. Lead asset RTx-015 is in Phase 1/2 for retinitis pigmentosa, with the Berkeley opsin engineering and AAV delivery IP forming the technical moat.Use of Proceeds and VisionCapital goes into Phase 2 enrollment and readouts, expansion into geographic atrophy and dry AMD, and scaling GMP manufacturing. The longer-term aim is a platform that addresses both inherited and acquired retinal diseases.Market ContextThe optogenetics field is small but heating up. Direct competitors include Nanoscope Therapeutics, Bionic Sight and GenSight Biologics. Editas takes a different angle with gene editing.5. Courier Health Raises $50M Series B For Biopharma Patient PlatformDeal OverviewStage: Series BSector: Healthtech / biopharma SaaSGeography: New York, USRound size: $50MLead investor: Oak HC/FTInvestor ProfileOak HC/FT led the round, joined by Norwest and Work-Bench from earlier stages. Oak has a long bench of payer- and biopharma-focused investments, which is the right neighborhood for Courier's customers.Company and LeadershipCourier Health was founded in 2021 in NYC by CEO Hayley Brasher, who came out of Flatiron Health. The team has built around rare-disease and specialty therapeutics from the start.Problem and OpportunityBiopharma manufacturers run patient-services programs through a stitched-together stack of Salesforce builds, hub-vendor portals and spreadsheets. The data lives in silos, the workflows are manual, and the patient experience suffers. Specialty drugs are where this hurts most.Product and TechnologyThe platform is a CRM and patient-experience system purpose-built for biopharma. It unifies hub-services data, patient-support program activity, field-team CRM and analytics into one workflow. AI agents handle case management and adherence outreach. Compliance is GxP and HIPAA-ready.Use of Proceeds and VisionFunds go into AI and product development, enterprise sales targeting the top-20 pharma companies, and expansion into commercial analytics and adjacent rare-disease workflows.Market ContextUS specialty and rare-disease drugs make up a $300B+ market with very high patient-services costs per patient. Veeva CRM offers hub modules but isn't purpose-built for patient services. Other competitors include TrialCard/Mercalis, AssistRx and ConnectiveRx.6. Alcatraz AI Adds $50M To Scale Facial-Auth Access ControlDeal OverviewStage: Series B+Sector: Cybersecurity / physical access controlGeography: Cupertino, USRound size: $50M (total funding now past $100M)Investors: Ten Eleven Ventures, Kleiner Perkins, JCI VenturesInvestor ProfileTen Eleven and Kleiner Perkins extended from earlier rounds. JCI Ventures (Johnson Controls) is strategic, which matters because JCI sells the access-control panels Alcatraz integrates with.Company and LeadershipAlcatraz AI was founded in 2016 in Cupertino by CEO Vince Gaydarzhiev, who came out of the Apple Face ID team. The company has been building hardware and shipping into enterprise deployments for nearly a decade.Problem and OpportunityBadges get lost, shared, cloned and forgotten. PINs get written down. Enterprises have spent years trying to upgrade physical access without forcing employees through a clunky biometric step at every door.Product and TechnologyThe Rock is a 3D facial-authentication reader that mounts at doors, turnstiles and secure rooms. It does depth sensing and on-device ML so biometric data doesn't leave the device, then talks to existing access-control panels from Lenel, Genetec and CCURE. The hardware-plus-software approach is what most software-only competitors lack.Use of Proceeds and VisionCapital funds manufacturing scale-up, channel-partner expansion, software development for analytics and identity, and international growth.Market ContextPhysical access control is roughly a $10B/year category and growing as enterprises move off badges. Alcatraz competes with Wicket, Oosto, IDEMIA and Suprema, plus a fringe of camera-based identity vendors trying to cover the same use case without dedicated hardware.Lessons For FoundersVertical SaaS still raises at growth rounds when the data graph is hard to copy. AcuityMD and Courier Health both won by owning the underlying taxonomy of their industry, not just shipping a workflow tool.Founder pedigree compresses fundraising cycles. Omni's Looker alumni and Ray Therapeutics' Berkeley scientific founders both raised faster and at better terms than first-time founders in the same categories.Company-creation biotechs keep working. Tortugas launched with $100M and a clinical pipeline on day one because Foresite and Versant assembled the assets before the press release. If you're building in CNS, the studio path is now a real option.Hardware companies can raise late-stage rounds if the software margin is real. Alcatraz crossed $100M total funding because The Rock has on-device ML and integrates with existing infrastructure, not because it's a cheap camera.Strategic capital with a distribution angle still moves the needle. JCI Ventures on Alcatraz's cap table is worth more than its dollar value because JCI sells the panels Alcatraz plugs into.](#use-of-proceeds-and-visionthe-plan-is-to-extend-ai-agent-capabilities-grow-the-field-sales-and-customer-success-teams-expand-internationally-and-move-into-adjacent-products-like-marketing-and-market-access-the-pitch-to-investors-is-that-acuitymd-becomes-the-veeva-of-medical-devices-market-contextthe-global-medical-device-market-clears-$600b+-annually-and-employs-thousands-of-commercial-reps-veeva-has-limited-medtech-presence-the-rest-of-the-field-is-definitive-healthcare-iqvia-h1-and-a-long-tail-of-in-house-bi-builds-4-ray-therapeutics-adds-$75m-for-optogenetic-vision-restorationdeal-overviewstage-series-b+sector-healthtech-gene-therapygeography-south-san-francisco-usround-size-$75minvestors-deerfield-management-norwest-venture-partners-casdin-capitalinvestor-profiledeerfield-norwest-and-casdin-all-extended-from-prior-rounds-the-syndicate-is-unusually-concentrated-for-a-clinical-stage-biotech-which-suggests-strong-conviction-from-existing-backers-rather-than-a-competitive-new-money-round-company-and-leadershipray-therapeutics-was-founded-in-2021-by-ceo-paul-bresge-with-scientific-co-founders-from-uc-berkeley-who-pioneered-optogenetics-the-company-has-been-operating-in-south-san-francisco-since-launch-problem-and-opportunityretinitis-pigmentosa-affects-roughly-1-in-4-000-people-globally-and-has-no-broadly-approved-treatment-luxturna-works-only-for-patients-with-a-specific-rpe65-mutation-most-rp-patients-have-nothing-product-and-technologyray-s-approach-is-mutation-agnostic-aav-vectors-deliver-light-sensitive-opsins-to-retinal-cells-restoring-some-level-of-vision-regardless-of-which-gene-is-broken-lead-asset-rtx-015-is-in-phase-1-2-for-retinitis-pigmentosa-with-the-berkeley-opsin-engineering-and-aav-delivery-ip-forming-the-technical-moat-use-of-proceeds-and-visioncapital-goes-into-phase-2-enrollment-and-readouts-expansion-into-geographic-atrophy-and-dry-amd-and-scaling-gmp-manufacturing-the-longer-term-aim-is-a-platform-that-addresses-both-inherited-and-acquired-retinal-diseases-market-contextthe-optogenetics-field-is-small-but-heating-up-direct-competitors-include-nanoscope-therapeutics-bionic-sight-and-gensight-biologics-editas-takes-a-different-angle-with-gene-editing-5-courier-health-raises-$50m-series-b-for-biopharma-patient-platformdeal-overviewstage-series-bsector-healthtech-biopharma-saasgeography-new-york-usround-size-$50mlead-investor-oak-hc-ftinvestor-profileoak-hc-ft-led-the-round-joined-by-norwest-and-work-bench-from-earlier-stages-oak-has-a-long-bench-of-payer-and-biopharma-focused-investments-which-is-the-right-neighborhood-for-courier-s-customers-company-and-leadershipcourier-health-was-founded-in-2021-in-nyc-by-ceo-hayley-brasher-who-came-out-of-flatiron-health-the-team-has-built-around-rare-disease-and-specialty-therapeutics-from-the-start-problem-and-opportunitybiopharma-manufacturers-run-patient-services-programs-through-a-stitched-together-stack-of-salesforce-builds-hub-vendor-portals-and-spreadsheets-the-data-lives-in-silos-the-workflows-are-manual-and-the-patient-experience-suffers-specialty-drugs-are-where-this-hurts-most-product-and-technologythe-platform-is-a-crm-and-patient-experience-system-purpose-built-for-biopharma-it-unifies-hub-services-data-patient-support-program-activity-field-team-crm-and-analytics-into-one-workflow-ai-agents-handle-case-management-and-adherence-outreach-compliance-is-gxp-and-hipaa-ready-use-of-proceeds-and-visionfunds-go-into-ai-and-product-development-enterprise-sales-targeting-the-top-20-pharma-companies-and-expansion-into-commercial-analytics-and-adjacent-rare-disease-workflows-market-contextus-specialty-and-rare-disease-drugs-make-up-a-$300b+-market-with-very-high-patient-services-costs-per-patient-veeva-crm-offers-hub-modules-but-isn-t-purpose-built-for-patient-services-other-competitors-include-trialcard-mercalis-assistrx-and-connectiverx-6-alcatraz-ai-adds-$50m-to-scale-facial-auth-access-controldeal-overviewstage-series-b+sector-cybersecurity-physical-access-controlgeography-cupertino-usround-size-$50m-total-funding-now-past-$100m-investors-ten-eleven-ventures-kleiner-perkins-jci-venturesinvestor-profileten-eleven-and-kleiner-perkins-extended-from-earlier-rounds-jci-ventures-johnson-controls-is-strategic-which-matters-because-jci-sells-the-access-control-panels-alcatraz-integrates-with-company-and-leadershipalcatraz-ai-was-founded-in-2016-in-cupertino-by-ceo-vince-gaydarzhiev-who-came-out-of-the-apple-face-id-team-the-company-has-been-building-hardware-and-shipping-into-enterprise-deployments-for-nearly-a-decade-problem-and-opportunitybadges-get-lost-shared-cloned-and-forgotten-pins-get-written-down-enterprises-have-spent-years-trying-to-upgrade-physical-access-without-forcing-employees-through-a-clunky-biometric-step-at-every-door-product-and-technologythe-rock-is-a-3d-facial-authentication-reader-that-mounts-at-doors-turnstiles-and-secure-rooms-it-does-depth-sensing-and-on-device-ml-so-biometric-data-doesn-t-leave-the-device-then-talks-to-existing-access-control-panels-from-lenel-genetec-and-ccure-the-hardware-plus-software-approach-is-what-most-software-only-competitors-lack-use-of-proceeds-and-visioncapital-funds-manufacturing-scale-up-channel-partner-expansion-software-development-for-analytics-and-identity-and-international-growth-market-contextphysical-access-control-is-roughly-a-$10b-year-category-and-growing-as-enterprises-move-off-badges-alcatraz-competes-with-wicket-oosto-idemia-and-suprema-plus-a-fringe-of-camera-based-identity-vendors-trying-to-cover-the-same-use-case-without-dedicated-hardware-lessons-for-foundersvertical-saas-still-raises-at-growth-rounds-when-the-data-graph-is-hard-to-copy-acuitymd-and-courier-health-both-won-by-owning-the-underlying-taxonomy-of-their-industry-not-just-shipping-a-workflow-tool-founder-pedigree-compresses-fundraising-cycles-omni-s-looker-alumni-and-ray-therapeutics-berkeley-scientific-founders-both-raised-faster-and-at-better-terms-than-first-time-founders-in-the-same-categories-company-creation-biotechs-keep-working-tortugas-launched-with-$100m-and-a-clinical-pipeline-on-day-one-because-foresite-and-versant-assembled-the-assets-before-the-press-release-if-you-re-building-in-cns-the-studio-path-is-now-a-real-option-hardware-companies-can-raise-late-stage-rounds-if-the-software-margin-is-real-alcatraz-crossed-$100m-total-funding-because-the-rock-has-on-device-ml-and-integrates-with-existing-infrastructure-not-because-it-s-a-cheap-camera-strategic-capital-with-a-distribution-angle-still-moves-the-needle-jci-ventures-on-alcatraz-s-cap-table-is-worth-more-than-its-dollar-value-because-jci-sells-the-panels-alcatraz-plugs-into) - [Market Context](#market-context-2) - [4. Ray Therapeutics Adds $75M For Optogenetic Vision Restoration](#4-ray-therapeutics-adds-$75m-for-optogenetic-vision-restoration) [Deal Overview](#deal-overview-3) - [Investor Profile](#investor-profile-3) - [Company and Leadership](#company-and-leadership-3) - [Problem and Opportunity](#problem-and-opportunity-3) - [Product and Technology](#product-and-technology-3) - [Use of Proceeds and Vision](#use-of-proceeds-and-vision-2) - [Market Context](#market-context-3) - [5. Courier Health Raises $50M Series B For Biopharma Patient Platform](#5-courier-health-raises-$50m-series-b-for-biopharma-patient-platform) [Deal Overview](#deal-overview-4) - [Investor Profile](#investor-profile-4) - [Company and Leadership](#company-and-leadership-4) - [Problem and Opportunity](#problem-and-opportunity-4) - [Product and Technology](#product-and-technology-4) - [Use of Proceeds and Vision](#use-of-proceeds-and-vision-3) - [Market Context](#market-context-4) - [6. Alcatraz AI Adds $50M To Scale Facial-Auth Access Control](#6-alcatraz-ai-adds-$50m-to-scale-facial-auth-access-control) [Deal Overview](#deal-overview-5) - [Investor Profile](#investor-profile-5) - [Company and Leadership](#company-and-leadership-5) - [Problem and Opportunity](#problem-and-opportunity-5) - [Product and Technology](#product-and-technology-5) - [Use of Proceeds and Vision](#use-of-proceeds-and-vision-4) - [Market Context](#market-context-5) - [Lessons For Founders](#lessons-for-founders) ## 1. Omni Raises $120M For AI-Native BI ### Deal Overview - Stage: Series C - Sector: SaaS / business intelligence - Geography: San Francisco, US - Round size: $120M - Lead investor: ICONIQ ### Investor Profile ICONIQ led, with Redpoint Ventures and First Round Capital following on. ICONIQ has been the late-stage lead behind Snowflake, Databricks and Airtable, so this is a familiar bet on data-stack winners. First Round and Redpoint were already on the cap table from earlier rounds. ### Company and Leadership Omni was started in 2022 by Colin Zima, Christopher Merrick and Jamie Davidson, three of the founding engineers and product leaders behind Looker. Zima ran analytics at Looker and is the public face of the company. The team has shipped data-modeling tooling for over a decade. ### Problem and Opportunity Most BI tools force a choice. Looker gives you a clean semantic model but locks analysts out of ad-hoc SQL. Tableau and Power BI let anyone slice data but produce dashboards that nobody trusts. Omni’s bet is that modern teams want both, and that the warehouse-native generation of BI is still up for grabs. ### Product and Technology The product pairs a governed semantic layer with SQL and spreadsheet-style workbooks. Analysts model data once and business users explore through SQL, Excel-like sheets or natural-language prompts. Embedded analytics and AI agents are built in rather than bolted on, and the platform plugs directly into Snowflake, Databricks and BigQuery. ### Use of Proceeds and Vision The capital goes into engineering and AI work, embedded-analytics expansion, enterprise sales and international growth. Zima has been clear about the goal: build what Looker would look like if it were started today. ### Market Context BI is a $30B+ category consolidating around warehouse-native tools. Omni is up against Looker (now Google), Tableau (Salesforce), Power BI, Mode, Hex, Sigma and ThoughtSpot. The opening is real because the incumbents are stuck inside larger platforms with slower release cycles. ## 2. Tortugas Neuroscience Launches With $100M For CNS Pipeline ### Deal Overview - Stage: Series B+ (launch financing) - Sector: Healthtech / biotech - Geography: US - Round size: $100M - Lead investors: Foresite Capital, Versant Ventures ### Investor Profile Foresite and Versant have built and bankrolled some of the most successful CNS biotechs of the last cycle. Both firms run company-creation studios, which is how Tortugas came together rather than a traditional founding story. ### Company and Leadership Tortugas launched in April 2026 with a portfolio of clinical-stage assets in-licensed or acquired from pharma partners. The leadership bench is filled with veteran CNS-drug-development operators, which is the standard playbook for these venture-built biotechs. ### Problem and Opportunity Schizophrenia, focal epilepsy and tinnitus are among the largest CNS markets with the worst patient outcomes. Tinnitus alone has no approved drug. Pharma majors have been reluctant to commit, leaving room for focused biotechs to run the next wave of trials. ### Product and Technology The pipeline covers schizophrenia, tinnitus and focal epilepsy with Phase 1/2 programs spanning receptor modulators and neural-circuit therapies. Because assets came in pre-clinical-data, execution risk is meaningfully lower than a typical Series A biotech. ### Use of Proceeds and Vision Funds will push the three lead programs through clinical trials, manufacturing and regulatory work. The team is targeting multiple Phase 2/3 readouts between 2027 and 2029. ### Market Context Schizophrenia is roughly $8B in annual sales, epilepsy $9B, and tinnitus is multi-billion in latent demand. Recent exits set the comp set: Karuna sold to BMS, Cerevel went to AbbVie. Public peers include Neumora and Sage Therapeutics. ## 3. AcuityMD Raises $80M Series C At $955M Valuation ### Deal Overview - Stage: Series C - Sector: Healthtech / medtech commercial software - Geography: Boston, US - Round size: $80M - Valuation: $955M - Lead investor: Iconiq Growth ### Investor Profile Iconiq Growth led, with Benchmark and Redpoint extending earlier positions. Benchmark has been on the cap table since the early days, which is unusual for a vertical SaaS company. ### Company and Leadership [AcuityMD](https://www.acuitymd.com) was founded in 2020 by CEO Mike Monovoukas and a team of ex-medtech operators. The Boston-based company is now closing in on unicorn status after this round. ### Problem and Opportunity Medtech sales reps have to know which surgeons do which procedures at which hospitals. That data exists across claims feeds, physician taxonomies and procedure codes, but no single system stitches it together for commercial use. Reps default to spreadsheets and stale account lists. ### Product and Technology The platform is a commercial-intelligence and CRM stack purpose-built for device makers. It links physicians, procedures, devices and hospitals into one data graph, then layers AI copilots on top for call planning, account research and rep coaching. Most major device manufacturers are already customers. ### Use of Proceeds and Vision